Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-112776 · Präparat HOS-093755
Tabulated summary of adverse reactions
Multiple Myeloma
Undesirable effects in Table 7 were considered by the investigators to have at least a possible or
probable causal relationship to VELCADE. These adverse reactions are based on an integrated data set
of 5,476 patients of whom 3,996 were treated with VELCADE at 1.3 mg/m2 and included in Table 7.
Overall, VELCADE was administered for the treatment of multiple myeloma in 3,974 patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 3022ae5ff1e6798c8330868e9a8d642dcb52ef2eb623103839ab5bdac01241de · Zeichen 615–1057 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-112777 · Präparat HOS-093755
Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are
defined as: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100);
rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the
available data). Within each frequency grouping, undesirable effects are presented in order of
decreasing seriousness. Table 7 has been generated using Version 14.1 of the MedDRA.
Post-marketing adverse reactions not seen in clinical trials are also included.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 2357b438c7e904dfc31c91ca5a3a5bcf920cf2470bfb57b1e734b3dae81a6cb8 · Zeichen 1059–1606 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-112778 · Präparat HOS-093755
Table 7: Adverse reactions in patients with Multiple Myeloma treated with VELCADE in clinical
trials, and all post-marketing adverse reactions regardless of indication#
System Organ
Class Incidence Adverse reaction
Infections and Common Herpes zoster (inc disseminated & ophthalmic), Pneumonia*,
infestations Herpes simplex*, Fungal infection*
Uncommon Infection*, Bacterial infections*, Viral infections*, Sepsis
(inc septic shock)*, Bronchopneumonia, Herpes virus
infection*, Meningoencephalitis herpetic#, Bacteraemia (inc
staphylococcal), Hordeolum, Influenza, Cellulitis, Device
related infection, Skin infection*, Ear infection*,
Staphylococcal infection, Tooth infection*
Rare Meningitis (inc bacterial), Epstein-Barr virus infection,
Genital herpes, Tonsillitis, Mastoiditis, Post viral fatigue
syndrome
Neoplasms Rare Neoplasm malignant, Leukaemia plasmacytic, Renal cell
benign, malignant carcinoma, Mass, Mycosis fungoides, Neoplasm benign*
and unspecified
(incl cysts and
polyps)
Blood and Very Common Thrombocytopenia*, Neutropenia*, Anaemia*
lymphatic system Common Leukopenia*, Lymphopenia*
disorders Uncommon Pancytopenia*, Febrile neutropenia, Coagulopathy*,
Leukocytosis*, Lymphadenopathy, Haemolytic anaemia#
Rare Disseminated intravascular coagulation, Thrombocytosis*,
Hyperviscosity syndrome, Platelet disorder NOS, Thrombotic
microangiopathy (inc thrombocytopenic purpura) #, Blood
disorder NOS, Haemorrhagic diathesis, Lymphocytic
infiltration
Immune system Uncommon Angioedema#, Hypersensitivity*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage b4f39087891efc129d6737d403c6f0f638b768bdfe65cf992d3b32ea54c4f85e · Zeichen 1608–3962 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 14–15
HOS-112779 · Präparat HOS-093755
14
Rare Anaphylactic shock, Amyloidosis, Type III immune complex
mediated reaction
Endocrine Uncommon Cushing's syndrome*, Hyperthyroidism*, Inappropriate
disorders antidiuretic hormone secretion
Rare Hypothyroidism
Metabolism and Very Common Decreased appetite
nutrition disorders Common Dehydration, Hypokalaemia*, Hyponatraemia*, Blood
glucose abnormal*, Hypocalcaemia*, Enzyme abnormality*
Uncommon Tumour lysis syndrome, Failure to thrive*,
Hypomagnesaemia*, Hypophosphataemia*, Hyperkalaemia*,
Hypercalcaemia*, Hypernatraemia*, Uric acid abnormal*,
Diabetes mellitus*, Fluid retention
Rare Hypermagnesaemia*, Acidosis, Electrolyte imbalance*, Fluid
overload, Hypochloraemia*, Hypovolaemia,
Hyperchloraemia*, Hyperphosphataemia*, Metabolic
disorder, Vitamin B complex deficiency, Vitamin B12
deficiency, Gout, Increased appetite, Alcohol intolerance
Psychiatric Common Mood disorders and disturbances*, Anxiety disorder*, Sleep
disorders disorders and disturbances*
Uncommon Mental disorder*, Hallucination*, Psychotic disorder*,
Confusion*, Restlessness
Rare Suicidal ideation*, Adjustment disorder, Delirium, Libido
decreased
Nervous system Very Common Neuropathies*, Peripheral sensory neuropathy, Dysaesthesia*,
disorders Neuralgia*
Common Motor neuropathy*, Loss of consciousness (inc syncope),
Dizziness*, Dysgeusia*, Lethargy, Headache*
Uncommon Tremor, Peripheral sensorimotor neuropathy, Dyskinesia*,
Cerebellar coordination and balance disturbances*, Memory
loss (exc dementia)*, Encephalopathy*, Posterior Reversible
Encephalopathy Syndrome#, Neurotoxicity, Seizure
disorders*, Post herpetic neuralgia, Speech disorder*,
Restless legs syndrome, Migraine, Sciatica, Disturbance in
attention, Reflexes abnormal*, Parosmia
Rare Cerebral haemorrhage*, Haemorrhage intracranial (inc
subarachnoid)*, Brain oedema, Transient ischaemic attack,
Coma, Autonomic nervous system imbalance, Autonomic
neuropathy, Cranial palsy*, Paralysis*, Paresis*, Presyncope,
Brain stem syndrome, Cerebrovascular disorder, Nerve root
lesion, Psychomotor hyperactivity, Spinal cord compression,
Cognitive disorder NOS, Motor dysfunction, Nervous system
disorder NOS, Radiculitis, Drooling, Hypotonia, Guillain-
Barré syndrome#, Demyelinating polyneuropathy#
Eye disorders Common Eye swelling*, Vision abnormal*, Conjunctivitis*
Uncommon Eye haemorrhage*, Eyelid infection*, Chalazion# ,
Blepharitis#, Eye inflammation*, Diplopia, Dry eye*, Eye
irritation*, Eye pain, Lacrimation increased, Eye discharge
Rare Corneal lesion*, Exophthalmos, Retinitis, Scotoma, Eye
disorder (inc. eyelid) NOS, Dacryoadenitis acquired,
Photophobia, Photopsia, Optic neuropathy#, Different degrees
of visual impairment (up to blindness)*
Ear and labyrinth Common Vertigo*
disorders Uncommon Dysacusis (inc tinnitus)*,Hearing impaired (up to and inc
deafness), Ear discomfort*
Rare Ear haemorrhage, Vestibular neuronitis, Ear disorder NOS
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 76eb623584d537571be209258ac92a7abf8d3ca22e1eb9fedf9585c558c586ce · Zeichen 4015–8500 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 15–16
HOS-112780 · Präparat HOS-093755
15
Cardiac disorders Uncommon Cardiac tamponade#, Cardio-pulmonary arrest*, Cardiac
fibrillation (inc atrial), Cardiac failure (inc left and right
ventricular)*, Arrhythmia*, Tachycardia*, Palpitations,
Angina pectoris, Pericarditis (inc pericardial effusion)*,
Cardiomyopathy*, Ventricular dysfunction*, Bradycardia
Rare Atrial flutter, Myocardial infarction*, Atrioventricular block*,
Cardiovascular disorder (inc cardiogenic shock), Torsade de
pointes, Angina unstable, Cardiac valve disorders*, Coronary
artery insufficiency, Sinus arrest
Vascular disorders Common Hypotension*, Orthostatic hypotension, Hypertension*
Uncommon Cerebrovascular accident#, Deep vein thrombosis*,
Haemorrhage*, Thrombophlebitis (inc superficial),
Circulatory collapse (inc hypovolaemic shock), Phlebitis,
Flushing*, Haematoma (inc perirenal)*, Poor peripheral
circulation*, Vasculitis, Hyperaemia (inc ocular)*
Rare Peripheral embolism, Lymphoedema, Pallor, Erythromelalgia,
Vasodilatation, Vein discolouration, Venous insufficiency
Respiratory, Common Dyspnoea*, Epistaxis, Upper/lower respiratory tract
thoracic and infection*, Cough*
mediastinal Uncommon Pulmonary embolism, Pleural effusion, Pulmonary oedema
disorders (inc acute), Pulmonary alveolar haemorrhage#,
Bronchospasm, Chronic obstructive pulmonary disease*,
Hypoxaemia*, Respiratory tract congestion*, Hypoxia,
Pleurisy*, Hiccups, Rhinorrhoea, Dysphonia, Wheezing
Rare Respiratory failure, Acute respiratory distress syndrome,
Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension,
Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis,
Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis,
Bronchial disorder*, Hypocapnia*, Interstitial lung disease,
Lung infiltration, Throat tightness, Dry throat, Increased
upper airway secretion, Throat irritation, Upper-airway cough
syndrome
Gastrointestinal Very Common Nausea and vomiting symptoms*, Diarrhoea*, Constipation
disorders Common Gastrointestinal haemorrhage (inc mucosal)*, Dyspepsia,
Stomatitis*, Abdominal distension, Oropharyngeal pain*,
Abdominal pain (inc gastrointestinal and splenic pain)*, Oral
disorder*, Flatulence
Uncommon Pancreatitis (inc chronic)*, Haematemesis, Lip swelling*,
Gastrointestinal obstruction (inc small intestinal obstruction,
ileus)*, Abdominal discomfort, Oral ulceration*, Enteritis*,
Gastritis*, Gingival bleeding, Gastrooesophageal reflux
disease*, Colitis (inc clostridium difficile)*, Colitis
ischaemic#, Gastrointestinal inflammation*, Dysphagia,
Irritable bowel syndrome, Gastrointestinal disorder NOS,
Tongue coated, Gastrointestinal motility disorder*, Salivary
gland disorder*
Rare Pancreatitis acute, Peritonitis*, Tongue oedema*, Ascites,
Oesophagitis, Cheilitis, Faecal incontinence, Anal sphincter
atony, Faecaloma*, Gastrointestinal ulceration and
perforation*, Gingival hypertrophy, Megacolon, Rectal
discharge, Oropharyngeal blistering*, Lip pain, Periodontitis,
Anal fissure, Change of bowel habit, Proctalgia, Abnormal
faeces
Hepatobiliary Common Hepatic enzyme abnormality*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage e295c15fcf46b9f0cf61227e0a4ab9649f62ea48ae8b2ba1e40c48070ada01ea · Zeichen 8546–13141 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 16–17
HOS-112781 · Präparat HOS-093755
16
Uncommon Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis
Rare Hepatic failure, Hepatomegaly, Budd-Chiari syndrome,
Cytomegalovirus hepatitis, Hepatic haemorrhage,
Cholelithiasis
Skin and Common Rash*, Pruritus*, Erythema, Dry skin
subcutaneous Uncommon Erythema multiforme, Urticaria, Acute febrile neutrophilic
tissue disorders dermatosis, Toxic skin eruption, Toxic epidermal necrolysis#,
Stevens-Johnson syndrome#, Dermatitis*, Hair disorder*,
Petechiae, Ecchymosis, Skin lesion, Purpura, Skin mass*,
Psoriasis, Hyperhidrosis, Night sweats, Decubitus ulcer#,
Acne*, Blister*, Pigmentation disorder*
Rare Skin reaction, Jessner's lymphocytic infiltration, Palmar-
plantar erythrodysaesthesia syndrome, Haemorrhage
subcutaneous, Livedo reticularis, Skin induration, Papule,
Photosensitivity reaction, Seborrhoea, Cold sweat, Skin
disorder NOS, Erythrosis, Skin ulcer, Nail disorder
Musculoskeletal Very Common Musculoskeletal pain*
and connective Common Muscle spasms*, Pain in extremity, Muscular weakness
tissue disorders Uncommon Muscle twitching, Joint swelling, Arthritis*, Joint stiffness,
Myopathies*,Sensation of heaviness
Rare Rhabdomyolysis, Temporomandibular joint syndrome,
Fistula, Joint effusion, Pain in jaw, Bone disorder,
Musculoskeletal and connective tissue infections and
inflammations*, Synovial cyst
Renal and urinary Common Renal impairment*
disorders Uncommon Renal failure acute, Renal failure chronic*, Urinary tract
infection*, Urinary tract signs and symptoms*, Haematuria*,
Urinary retention, Micturition disorder*, Proteinuria,
Azotaemia, Oliguria*, Pollakiuria
Rare Bladder irritation
Reproductive Uncommon Vaginal haemorrhage, Genital pain*, Erectile dysfunction,
system and breast Rare Testicular disorder*, Prostatitis, Breast disorder female,
disorders Epididymal tenderness, Epididymitis, Pelvic pain, Vulval
ulceration
Congenital, Rare Aplasia, Gastrointestinal malformation, Ichthyosis
familial and
genetic disorders
General disorders Very Common Pyrexia*, Fatigue, Asthenia
and administration Common Oedema (inc peripheral), Chills, Pain*, Malaise*
site conditions Uncommon General physical health deterioration*, Face oedema*,
Injection site reaction*, Mucosal disorder*, Chest pain, Gait
disturbance, Feeling cold, Extravasation*, Catheter related
complication*, Change in thirst*, Chest discomfort, Feeling
of body temperature change*, Injection site pain*
Rare Death (inc sudden), Multi-organ failure, Injection site
haemorrhage*, Hernia(inc hiatus)*, Impaired healing*,
Inflammation, Injection site phlebitis*, Tenderness, Ulcer,
Irritability, Non-cardiac chest pain, Catheter site pain,
Sensation of foreign body
Investigations Common Weight decreased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 556d8299c0ea38c3ef85ea25ee62b71732974b20bc0f4ae1cf0b1857ead394ee · Zeichen 13189–17103 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 17–18
HOS-112782 · Präparat HOS-093755
17
Uncommon Hyperbilirubinaemia*, Protein analyses abnormal*, Weight
increased, Blood test abnormal*,C-reactive protein increased
Rare Blood gases abnormal*, Electrocardiogram abnormalities (inc
QT prolongation)*, International normalised ratio abnormal*,
Gastric pH decreased, Platelet aggregation increased,
Troponin I increased, Virus identification and serology*,
Urine analysis abnormal*
Injury, poisoning Uncommon Fall, Contusion
and procedural Rare Transfusion reaction, Fractures*, Rigors*, Face injury, Joint
complications injury*, Burns, Laceration, Procedural pain, Radiation
injuries*
Surgical and Rare Macrophage activation
medical
procedures
NOS=not otherwise specified
* Grouping of more than one MedDRA preferred term.
# Post-marketing adverse reaction regardless of indication
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 7e528e5c666a846944db89e2725d3ce010b542fb8bba32801938f9e9921d6f5e · Zeichen 17151–18404 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 18
HOS-112783 · Präparat HOS-093755
Mantle Cell Lymphoma (MCL)
The safety profile of VELCADE in 240 MCL patients treated with VELCADE at 1.3 mg/m2 in
combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP), versus
242 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
[R-CHOP] was relatively consistent to that observed in patients with multiple myeloma with main
differences described below. Additional adverse drug reactions identified associated with the use of
the combination therapy (VcR-CAP) were hepatitis B infection (< 1%) and myocardial ischaemia
(1.3%). The similar incidences of these events in both treatment arms, indicated that these adverse
drug reactions are not attributable to VELCADE alone. Notable differences in the MCL patient
population as compared to patients in the multiple myeloma studies were a ≥ 5% higher incidence of
the haematological adverse reactions (neutropenia, thrombocytopenia, leukopenia, anaemia,
lymphopenia), peripheral sensory neuropathy, hypertension, pyrexia, pneumonia, stomatitis, and hair
disorders.
Adverse drug reactions identified as those with a ≥ 1% incidence, similar or higher incidence in the
VcR-CAP arm and with at least a possible or probable causal relationship to the components of the
VcR-CAP arm, are listed in Table 8 below. Also included are adverse drug reactions identified in the
VcR-CAP arm that were considered by investigators to have at least a possible or probable causal
relationship to VELCADE based on historical data in the multiple myeloma studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage e0b93190a303c759ba690a7b74c16ee4c4ec03a179d92b89bcbb333ff0434dae · Zeichen 18406–19969 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 18
HOS-112784 · Präparat HOS-093755
Adverse reactions are listed below by system organ class and frequency grouping. Frequencies are
defined as: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100);
rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the
available data). Within each frequency grouping, undesirable effects are presented in order of
decreasing seriousness. Table 8 has been generated using Version 16 of the MedDRA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 9601ba1120afd4d4cfe46bf25600eb820a750c8b07a6a52774ed085d1a58c8ea · Zeichen 19971–20436 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 18
HOS-112785 · Präparat HOS-093755
Table 8: Adverse reactions in patients with Mantle Cell Lymphoma treated with VcR-CAP in a
clinical trial
System Organ
Class Incidence Adverse reaction
Infections and Very Common Pneumonia*
infestations Common Sepsis (inc septic shock)*, Herpes zoster (inc disseminated &
ophthalmic), Herpes virus infection*, Bacterial infections*,
Upper/lower respiratory tract infection*, Fungal infection*,
Herpes simplex*
Uncommon Hepatitis B, Infection*, Bronchopneumonia
Blood and Very Common Thrombocytopenia*, Febrile neutropenia, Neutropenia*,
lymphatic system Leukopenia*, Anaemia*, Lymphopenia*
disorders Uncommon Pancytopenia*
Immune system Common Hypersensitivity*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage afe66881fa2b40b8c96b71e6af9c87981e6866413f7d0933af7b1014ec93948c · Zeichen 20438–21375 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 18–19
HOS-112786 · Präparat HOS-093755
18
disorders Uncommon Anaphylactic reaction
Metabolism and Very Common Decreased appetite
nutrition disorders Common Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*,
Diabetes mellitus*, Fluid retention
Uncommon Tumour lysis syndrome
Psychiatric Common Sleep disorders and disturbances*
disorders
Nervous system Very Common Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*
disorders Common Neuropathies*, Motor neuropathy*, Loss of consciousness (inc
syncope), Encephalopathy*, Peripheral sensorimotor
neuropathy, Dizziness*, Dysgeusia*, Autonomic neuropathy
Uncommon Autonomic nervous system imbalance
Eye disorders Common Vision abnormal*
Ear and labyrinth Common Dysacusis (inc tinnitus)*
disorders Uncommon Vertigo*, Hearing impaired (up to and inc deafness)
Cardiac disorders Common Cardiac fibrillation (inc atrial), Arrhythmia*, Cardiac failure
(inc left and right ventricular)*, Myocardial ischaemia,
Ventricular dysfunction*
Uncommon Cardiovascular disorder (inc cardiogenic shock)
Vascular disorders Common Hypertension*, Hypotension*, Orthostatic hypotension
Respiratory, Common Dyspnoea*, Cough*, Hiccups
thoracic and Uncommon Acute respiratory distress syndrome, Pulmonary embolism,
mediastinal Pneumonitis, Pulmonary hypertension, Pulmonary oedema (inc
disorders acute)
Gastrointestinal Very Common Nausea and vomiting symptoms*, Diarrhoea*, Stomatitis*,
disorders Constipation
Common Gastrointestinal haemorrhage (inc mucosal)*, Abdominal
distension, Dyspepsia, Oropharyngeal pain*, Gastritis*, Oral
ulceration*, Abdominal discomfort, Dysphagia, Gastrointestinal
inflammation*, Abdominal pain (inc gastrointestinal and splenic
pain)*, Oral disorder*
Uncommon Colitis (inc clostridium difficile)*
Hepatobiliary Common Hepatotoxicity (inc liver disorder)
disorders Uncommon Hepatic failure
Skin and Very Common Hair disorder*
subcutaneous Common Pruritus*, Dermatitis*, Rash*
tissue disorders
Musculoskeletal Common Muscle spasms*, Musculoskeletal pain*, Pain in extremity
and connective
tissue disorders
Renal and urinary Common Urinary tract infection*
disorders
General disorders Very Common Pyrexia*, Fatigue, Asthenia
and administration Common Oedema (inc peripheral), Chills, Injection site reaction*,
site conditions Malaise*
Investigations Common Hyperbilirubinaemia*, Protein analyses abnormal*, Weight
decreased, Weight increased
* Grouping of more than one MedDRA preferred term.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage b2807230b39a12d0db55d1c501c87a9f5cc514fad20ddf2b4266826d5fa25ae1 · Zeichen 21438–24579 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 19
HOS-112787 · Präparat HOS-093755
Description of selected adverse reactions
Herpes zoster virus reactivation
Multiple Myeloma
Antiviral prophylaxis was administered to 26% of the patients in the Vc+M+P arm. The incidence of
herpes zoster among patients in the Vc+M+P treatment group was 17% for patients not administered
antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage eefe371af8b2e27ca465064609ac51f453eae083d8d9b0bc668f837081a84dbf · Zeichen 24581–24953 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 19–20
HOS-112788 · Präparat HOS-093755
19
Mantle cell lymphoma
Antiviral prophylaxis was administered to 137 of 240 patients (57%) in the VcR-CAP arm. The
incidence of herpes zoster among patients in the VcR-CAP arm was 10.7% for patients not
administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 1c513ea6a9613576e746573e13bda11eeed3f13c79f47db6d8345157ca25b7ed · Zeichen 25012–25335 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-112789 · Präparat HOS-093755
Hepatitis B Virus (HBV) reactivation and infection
Mantle cell lymphoma
HBV infection with fatal outcomes occurred in 0.8% (n=2) of patients in the non-VELCADE
treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP )
and 0.4% (n=1) of patients receiving VELCADE in combination with rituximab, cyclophosphamide,
doxorubicin, and prednisone (VcR-CAP). The overall incidence of hepatitis B infections was similar
in patients treated with VcR-CAP or with R-CHOP (0.8% vs 1.2% respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 30e69016e239f6cdc0fa5d6c41b323b092935c5272b143aa78d84148507b6182 · Zeichen 25337–25863 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-112790 · Präparat HOS-093755
Peripheral neuropathy in combination regimens
Multiple Myeloma
In trials in which VELCADE was administered as induction treatment in combination with
dexamethasone (study IFM-2005-01), and dexamethasone-thalidomide (study MMY-3010), the
incidence of peripheral neuropathy in the combination regimens is presented in the table below:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage e99b4e14f9693aea8de1170c889b44a13240a23e6a6c631ca868ca0a6f580f91 · Zeichen 25865–26197 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-112791 · Präparat HOS-093755
Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment
discontinuation due to peripheral neuropathy
IFM-2005-01 MMY-3010
VDDx VcDx TDx VcTDx
(N=239) (N=239) (N=126) (N=130)
Incidence of PN (%)
All GradePN 3 15 12 45
Grade 2 PN 1 10 2 31
Grade 3 PN <1 5 0 5
Discontinuation due to PN (%) <1 2 1 5
VDDx=vincristine, doxorubicin, dexamethasone; VcDx=VELCADE, dexamethasone; TDx=thalidomide, dexamethasone;
VcTDx=VELCADE, thalidomide, dexamethasone; PN=peripheral neuropathy
Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral
sensory neuropathy, and polyneuropathy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage af0df433459eb5ed39df6fc1bc5a5b73c17f0fee2597757f516b0b4ad9e239d7 · Zeichen 26199–27373 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-112792 · Präparat HOS-093755
Mantle cell lymphoma
In study LYM-3002 in which VELCADE was administered with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CAP), the incidence of peripheral neuropathy in the combination
regimens is presented in the table below:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 7853193994e01d171f6993dfb71c9f3a14da23953e9a2c567aebee7d1585604d · Zeichen 27375–27618 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-112793 · Präparat HOS-093755
Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment
discontinuation due to peripheral neuropathy
VcR-CAP R-CHOP
(N=240) (N=242)
Incidence of PN (%)
All GradePN 30 29
Grade 2 PN 18 9
Grade 3 PN 8 4
Discontinuation due to PN (%) 2 <1
VcR-CAP=VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
Peripheral neuropathy included the preferred terms: peripheral sensory neuropathy, neuropathy peripheral, peripheral
motor neuropathy, and peripheral sensorimotor neuropathy
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage e55c8b683b8dfaea1112b14355553d231f094f7b7b0a6c61882363111b88c640 · Zeichen 27620–28590 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-112794 · Präparat HOS-093755
Elderly MCL patients
42.9% and 10.4% of patients in the VcR-CAP arm were in the range 65-74 years and ≥ 75 years of
age, respectively. Although in patients aged ≥ 75 years, both VcR-CAP and R-CHOP were less
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage 1232cfe6408d48beefbcdd7e495ef0ffb1918c3b8fec3360f2a9d1ba66b3f472 · Zeichen 28593–28799 im Abschnitt
Nebenwirkungen · Velcade
VELCADE 1 mg powder for solution for injection · Abschnitt 4.8 · PDF-Seite 20–21
HOS-112795 · Präparat HOS-093755
20
tolerated, the serious adverse event rate in the VcR-CAP groups was 68%, compared to 42% in the
R-CHOP group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-18T11:00:00Z · SHA-256 0614ac01c21d9bc8ee31aa893ca113f39ffb5c8e9d9927b551be4a1d9803dc15 · Passage d04ede3f3fa9262bdcd97ca7fcd4fb23f02d7a4921d4dfdffd3aa9449e9c3ee5 · Zeichen 28861–28974 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.